Close Menu

Natera

News items for the in vitro diagnostics industry for the week of March 22, 2021.

News items for the in vitro diagnostics industry for the week of March 8, 2021.

During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.

The company reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.

Under the non-exclusive deal, Natera will use matched tumor and normal exome sequencing data from Personalis to validate the design of its Signatera ctDNA assays.

The researchers hope that donor-derived cell-free DNA testing to monitor rejection can help relieve racial disparities in heart transplant outcomes.

Natera alleges Inivata infringes its US Patent Nos. 10,262,755 and 10,597,709, which cover cancer monitoring and molecular residual disease testing.

Last year, the company processed more than 1 million tests, most of them for its reproductive health business, but interest in Prospera and Signatera is growing. 

News items for the in vitro diagnostics industry for the week of Dec. 21, 2020.

The company believes its tests can already help oncologists better assess post-surgery risk, though prospective validation would be necessary for broad claims.

Pages